Observational studyAdvances in therapy2025
Body Mass Index Progression, Development of Complications and Healthcare Costs Over 8 Years in UK Individuals Living With Overweight/Obesity.
Observational study in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Health Care Utilization Costs of GLP-1RA Use vs Bariatric Metabolic Surgery.JAMA network open · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA detailed understanding of the risk factors for and impacts of body mass index (BMI) progression in people living with obesity is vitally needed. In this retrospective observational study, we examined the relationships between BMI progression, obesity-related complications (ORCs) and healthcare costs in individuals living with overweight or obesity in the UK.
methodsData were from the Discover database of linked primary and secondary care records from 2.7 million individuals in North West London, UK. Included individuals were ≥ 18 years old, had a BMI of ≥ 25.0 kg/m
resultsIn total, 290,051 individuals were included, of whom 31.4% experienced BMI progression of ≥ 5% during follow-up, with most progression occurring from year 1 to year 3. Proportions of individuals with ≥ 5% BMI progression were highest in the following subgroups: 18-29 years (45.8%), 30-39 years (39.2%), polycystic ovary syndrome (41.4%), asthma (34.5%), depression (33.9%) and women (33.9%). Total annual healthcare costs per person per year were £1000 for those with no BMI progression, £1143 for those with 5 to < 10% progression and £1251 for those with ≥ 10% progression. Groups with progression were more likely to develop ≥ 3 ORCs than those without.
conclusionYounger adults, women and people with specific ORCs were most likely to experience BMI progression, which was associated with increased health and economic burden. Targeting high-risk subgroups with interventions to prevent weight gain could limit the clinical and economic impacts of obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.